SCHEDULE: TCG Crossover Fund II Boosts Nektar Therapeutics Stake

TCG Crossover Fund II, L.P. and affiliates report a 9.3% beneficial ownership stake in Nektar Therapeutics, including common stock and pre-funded warrants.

Summary

• TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu collectively reported beneficial ownership of 1,933,333 shares of Nektar Therapeutics common stock.
• This aggregate amount represents 9.3% of Nektar Therapeutics' outstanding common stock.
• The ownership consists of 266,666 shares of common stock and 1,666,667 shares issuable upon the exercise of certain pre-funded warrants.
• The calculation of the percentage of class is based on 19,018,573 shares of common stock outstanding as of July 31, 2025, as reported by Nektar Therapeutics in its Annual Report on Form 10-K filed on August 8, 2025, plus the 1,666,667 shares from pre-funded warrants held by TCG Crossover II.
• The reporting persons explicitly state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Nektar Therapeutics.

Sentiment

Score: 7

Explanation: The filing indicates a significant and passive stake by an institutional investor, which is generally a positive signal of confidence in the company's long-term prospects, without suggesting any immediate operational changes or activist intent.

Positives

• A significant 9.3% stake by TCG Crossover Fund II, a crossover fund, indicates a vote of confidence from an institutional investor in Nektar Therapeutics.
• The investment includes pre-funded warrants, suggesting a long-term strategic interest in the company's potential growth.

Risks

• The value of the investment is subject to the market performance of Nektar Therapeutics' common stock.
• The exercise of pre-funded warrants could lead to dilution for existing shareholders, although this is a common mechanism for capital raises.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Nektar Therapeutics.

Industry Context

This filing indicates continued institutional investor interest in Nektar Therapeutics, a biotechnology company. Such investments by crossover funds are common in the biotech sector, where companies often require significant capital for research, development, and commercialization, and investors seek long-term growth opportunities.

Stakeholder Impact

• Shareholders: The significant stake by TCG Crossover Fund II may be viewed positively, signaling institutional confidence in Nektar Therapeutics. The potential exercise of warrants could lead to minor dilution.

Key Dates

Recommendation

The filing reveals a substantial 9.3% beneficial ownership by TCG Crossover Fund II, a notable institutional investor. This indicates a strong vote of confidence in Nektar Therapeutics' long-term potential. While the filing itself doesn't provide new operational or financial performance data, the significant stake by a sophisticated investor suggests that the stock warrants a 'hold' recommendation for existing investors, and potential 'buy' consideration for new investors, pending further fundamental analysis of the company's financials and pipeline.

Keywords

Nektar Therapeutics, NKTR, TCG Crossover Fund II, Beneficial Ownership, Schedule 13G, Common Stock, Pre-Funded Warrants, Biotechnology, Pharmaceuticals, Institutional Investment